Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

Phase 3

Completed

Conditions: Chronic Myelogenous Leukemia - Chronic Phase

Interventions: Drug: ABL001

First Posted Date: 2020-12-14

Last Posted Date: 2024-07-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 56

Registration Number: NCT04666259

Locations: 🇺🇸
Univ of TX MD Anderson Cancer Cntr ., Houston, Texas, United States
🇺🇸
Uni of Cincinnati Medical Center ., Cincinnati, Ohio, United States
🇺🇸
Oncology Hematology Care Inc ., Cincinnati, Ohio, United States

and more 19 locations

A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

Phase 4

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Biological: Quadrivalent influenza vaccine
Drug: iDMT
Drug: Ofatumumab

First Posted Date: 2020-12-14

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 63

Registration Number: NCT04667117

Locations: 🇺🇸
The MS Center for Innovation in Care, Saint Louis, Missouri, United States
🇺🇸
Hope Research Institute Center Neurology and Spine, Phoenix, Arizona, United States
🇺🇸
Infinity Clinical Research LLC, Hollywood, Florida, United States

Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C

Phase 2

Completed

Conditions: Hypercholesterolemia
Heterozygous Familial Hypercholesterolemia

Interventions: Drug: Inclisiran sodium
Drug: Placebo

First Posted Date: 2020-12-14

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 312

Registration Number: NCT04666298

Locations: 🇯🇵
Novartis Investigative Site, Saga, Japan

A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Placebo
Drug: MAS825

First Posted Date: 2020-12-11

Last Posted Date: 2022-09-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 80

Registration Number: NCT04665154

Locations: 🇬🇧
Novartis Investigative Site, Mere Way, Nottingham, United Kingdom

A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections

Completed

Conditions: Neovascular Age-Related Macular Degeneration

Interventions: Drug: brolucizumab
Drug: ranibizumab
Drug: aflibercept

First Posted Date: 2020-12-10

Last Posted Date: 2024-06-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 494

Registration Number: NCT04662944

Locations: 🇪🇸
Novartis Investigative Site, Leon, Spain

An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients

Phase 4

Completed

Conditions: Sickle Cell Disease (SCD)

Interventions: Drug: crizanlizumab

First Posted Date: 2020-12-10

Last Posted Date: 2025-01-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 140

Registration Number: NCT04662931

Locations: 🇮🇳
Novartis Investigative Site, Kolkata, West Bengal, India

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia

Phase 3

Active, not recruiting

Conditions: Familial Hypercholesterolemia - Homozygous

Interventions: Drug: Inclisiran
Drug: Placebo

First Posted Date: 2020-12-09

Last Posted Date: 2024-06-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 13

Registration Number: NCT04659863

Locations: 🇺🇸
Excel Medical Clinical Trials LLC, Boca Raton, Florida, United States
🇱🇧
Hotel Dieu de France Hospital, Ashrafieh, Lebanon
🇹🇷
Novartis Investigative Site, Izmir, Turkey

and more 3 locations

Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

Phase 4

Recruiting

Conditions: Sickle Cell Disease

Interventions: Drug: Crizanlizumab

First Posted Date: 2020-12-08

Last Posted Date: 2024-10-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 130

Registration Number: NCT04657822

Locations: 🇺🇸
University Of Alabama, Birmingham, Alabama, United States
🇺🇸
Childrens National Hospital, Washington, District of Columbia, United States
🇺🇸
Augusta University Georgia Patient Treatment, Augusta, Georgia, United States

and more 5 locations

Digital Adherence Monitoring of Inhalative Therapy in Real- Life Conditions

Completed

Conditions: Asthma

Interventions: Combination Product: MF/IND/GLY plus sensor system
Drug: FDC therapy

First Posted Date: 2020-12-07

Last Posted Date: 2024-03-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 434

Registration Number: NCT04656223

Locations: 🇩🇪
Novartis Investigative Site, Wiesbaden, Germany

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia

Phase 3

Active, not recruiting

Conditions: Familial Hypercholesterolemia - Heterozygous

Interventions: Drug: Inclisiran
Drug: Placebo

First Posted Date: 2020-12-03

Last Posted Date: 2024-08-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 141

Registration Number: NCT04652726

Locations: 🇺🇸
Tucson Medical Center, Tucson, Arizona, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Wake Forest U of Health Sciences, Winston-Salem, North Carolina, United States

and more 28 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy